Selected items from the News and Latest Additions sections of www.palliativedrugs.com, the world’s leading palliative care website. Drug updates Hydromorphone ER 32mg launched in US A once daily modified-release hydromorphone 32mg tablet (Exalgo; Mallinckrodt, Hazelwood, MO) has been added to the existing product range of 8mg, 12mg and 16mg modified-release tablets for opioid-tolerant […]
Category: Updates from www.palliativedrugs.com
News and updates from www.palliativedrugs.com
Selected items from the News and Latest Additions sections of www.palliativedrugs.com, the world’s leading palliative care website. Safety updates FDA warn of skin injury with OTC rubefacients Rare cases of serious burns on the skin have been reported to the US Food and Drug Administration (FDA) where over-the-counter (OTC) topical muscle and joint […]
News and updates from www.palliativedrugs.com
Selected items from the News and Latest Additions sections of www.palliativedrugs.com, the world’s leading palliative care website. Hot topics Liverpool Care Pathway consensus statement Over 20 organisations have signed a consensus statement in support of the Liverpool Care Pathway for the dying patient, including professional bodies, third sector organizations, disease specific charities and […]
News and updates from www.palliativedrugs.com
Selected items from the News and Latest Additions sections of www.palliativedrugs.com, the world’s leading palliative care website. Hot topics DH consultation: Governance arrangements for controlled drugs The Department of Health (DH) is consulting on proposed changes to the governance arrangements for controlled drugs in England and Scotland, including the role and functions of […]
News and updates from www.palliativedrugs.com
Selected items from the News and Latest Additions sections of www.palliativedrugs.com, the world’s leading palliative care website. Drug updates Ketamine injection supply problems Pfizer UK has confirmed that there is a supply problem with ketamine (Ketalar) 10mg/mL and 100mg/mL injection. All orders for these products are now being re-directed to a Pfizer central […]
News and updates from www.palliativedrugs.com
Selected items from the News and Latest Additions sections of www.palliativedrugs.com, the world’s leading palliative care website. Drug updates NICE final draft guidance for denosumab The UK National Institute for Health and Clinical Excellence (NICE) has published final draft guidance on the use of denosumab for the treatment of bone metastases from solid tumours […]
News and updates from www.palliativedrugs.com
Selected items from the News and Latest Additions sections of www.palliativedrugs.com, the world’s leading palliative care website. Safety updates NPSA insulin passport deadline NHS organisations should ensure that by 31 August 2012 the following actions, outlined in the National Patient Safety Agency (NPSA) alert ‘The adult patient’s passport for safer use of insulin’ (NPSA/2011/PSA003), […]
News and updates from www.palliativedrugs.com
Selected items from the News and Latest Additions sections of www.palliativedrugs.com, the world’s leading palliative care website. Drug updates Olanzapine injection to be discontinued in UK Olanzapine injection, powder for reconstitution 5mg/mL, 10mg vial (Zyprexa; Lilly), is to be discontinued in theUK31st August 2012, for sales volume reasons. There is no generic or alternative […]
News and updates from www.palliativedrugs.com
Selected items from the News and Latest Additions sections of www.palliativedrugs.com, the world’s leading palliative care website. Hot topics FDA approve REMS for m/r opioids USFood and Drug administration (FDA) has approved a Risk Evaluation and Mitigation Strategy (REMS) program for all modified-release (m/r) opioids. Key components include prescriber training, updated patient information guides […]
News and updates from www.palliativedrugs.com
Selected items from the News and Latest Additions sections of www.palliativedrugs.com, the world’s leading palliative care website. Drug updates NICE consultation on denosumab The National Institute for Health and Clinical Excellence (NICE) has issued a second appraisal consultation document on the use of denosumab as a treatment to delay or prevent skeletal-related events […]